Optibrium and Integrated Chemistry Design Collaborat?e to Introduce Creative Compound Design on iPad
Optibrium and Integrated Chemistry Design, providers of software solutions and services for drug discovery, have announed the release of Asteris, a new iPad app that combines highly intuitive chemistry drawing tools with the most visually informative predictive modelling. Asteris enables creative researchers to rapidly evaluate new compound ideas when and where they want, no longer limited to sitting in an office or in front of a computer.
Asteris uses Chirys Draw’s patent pending chemical drawing tools, optimised specifically for the touch environment, allowing users to explore a much wider range of chemistry designs. Instant feedback from StarDrop’s predictive models, guided by the unique Glowing Molecule visualisation, dramatically reduces the time required to identify high quality compound designs. With Asteris users can calculate a range of “core properties”, such as logP, molecular weight, polar surface area, and hydrogen bond donors, and predict over ten ADME properties, including solubility, hERG inhibition, and CNS penetration.
Dr Matthew Segall, Optibrium’s CEO, commented: “We are very pleased to be working with Integrated Chemistry Design. The combination of our unique technologies in Asteris provides an innovative ideas space, giving users the flexibility to explore new compound designs, beyond the constraints of traditional computational tools. This collaboration furthers our on-going strategy to work with other leading developers of innovative solutions for drug discovery.”
Dr M. Catherine Johnson, President and CEO of Integrated Chemistry Design added: “We are excited that Asteris provides medicinal chemists with powerful tools for evaluating prospective drug ideas, and they can use Asteris anywhere, in meetings or on travel as well as in their offices. Using Asteris, drug designers will be able to assess ideas more quickly to converge on the most promising candidates for further study.”
Asteris will be launched at the American Chemical Society Spring 2014 National Meeting & Expo in Dallas, Texas from 16–20 March (visit Optibrium, booth #1516) and Integrated Chemistry Design (booth #400) to see Asteris in action. From 16 March, Asteris can be downloaded from the App Store.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.